Seek Returns logo

ALNY vs. ASND: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ALNY and ASND, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ALNY dominates in value with a market cap of 38.15 billion USD, eclipsing ASND’s 9.55 billion USD by roughly 4.00×.

ASND carries a higher beta at 0.40, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.

ASND is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALNY, which is purely domestic.

SymbolALNYASND
Company NameAlnylam Pharmaceuticals, Inc.Ascendis Pharma A/S
CountryUSDK
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology
CEODr. Yvonne L. Greenstreet M.B.A., M.D.Mr. Jan Moller Mikkelsen
Price292.58 USD158.1 USD
Market Cap38.15 billion USD9.55 billion USD
Beta0.170.40
ExchangeNASDAQNASDAQ
IPO DateJune 1, 2004January 28, 2015
ADRNoYes

Performance Comparison

This chart compares the performance of ALNY and ASND over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ALNY and ASND based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • Neither ALNY nor ASND turned a profit—both carry negative P/E ratios of -140.68 and -24.55, underscoring continued losses that pressure their valuations.
  • Analysts assign negative forward PEG ratios to both ALNY (-38.16) and ASND (-2.23), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
  • ASND carries a sub-zero price-to-book ratio of -44.19, indicating negative equity. In contrast, ALNY (P/B 328.68) has positive book value.
  • ALNY and ASND both consumed more free cash flow than they generated last year—P/FCF of -506.05 and -27.43, respectively—highlighting persistent liquidity pressure.
SymbolALNYASND
Price-to-Earnings Ratio (P/E, TTM)-140.68-24.55
Forward PEG Ratio (TTM)-38.16-2.23
Price-to-Sales Ratio (P/S, TTM)16.2522.88
Price-to-Book Ratio (P/B, TTM)328.68-44.19
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-506.05-27.43
EV-to-EBITDA (TTM)-251.73-35.74
EV-to-Sales (TTM)16.3723.78
EV-to-Free Cash Flow (TTM)-509.80-28.50

Dividend Comparison

Neither ALNY nor ASND currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolALNYASND
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ALNY and ASND, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND posts a quick ratio of 0.71, indicating limited coverage of short-term debts from its most liquid assets—while ALNY at 2.98 enjoys stronger liquidity resilience.
  • ALNY carries high leverage (debt-to-equity ratio 11.28), whereas ASND has negative equity (-4.46), each presenting distinct capital-structure concerns.
  • Both ALNY and ASND report negative interest coverage ratios (-0.79, -3.72), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
SymbolALNYASND
Current Ratio (TTM)3.041.04
Quick Ratio (TTM)2.980.71
Debt-to-Equity Ratio (TTM)11.28-4.46
Debt-to-Assets Ratio (TTM)0.310.80
Interest Coverage Ratio (TTM)-0.79-3.72